Bevacizumab in macular degeneration
Bevacizumab is a medication that has been used off-label to treat age-related macular degeneration (AMD), particularly the wet or neovascular form. AMD is a progressive eye condition that can lead to severe vision loss.
Bevacizumab belongs to a class of medications called anti-vascular endothelial growth factor (anti-VEGF) drugs. It works by inhibiting the activity of VEGF, a protein that promotes the growth of abnormal blood vessels in the retina, which is responsible for central vision.
In wet AMD, abnormal blood vessels grow underneath the macula, the central part of the retina. These vessels can leak fluid and blood, causing damage to the macula and leading to vision loss.
Bevacizumab is administered as an injection into the eye. It helps reduce the growth of new blood vessels, preventing leakage and slowing down the progression of the disease. However, it does not cure macular degeneration or reverse any existing damage.
While bevacizumab is not specifically FDA-approved for the treatment of macular degeneration, it has been widely used due to its effectiveness and cost-effectiveness. The FDA has approved other similar anti-VEGF drugs, such as ranibizumab (Lucentis) and aflibercept (Eylea), specifically for the treatment of wet AMD.
It is important to note that bevacizumab should only be used under the guidance of an ophthalmologist experienced in intravitreal injections. Like any medication, it can have potential side effects, including eye infections, retinal detachment, increased intraocular pressure, and inflammation.
It is recommended that individuals with macular degeneration consult with their eye doctor to discuss the potential benefits and risks of using bevacizumab as a treatment option.